key: cord-0963147-w7ekq1us authors: Boualila, Lina; Mrini, Basma; Tagmouti, Adam; Moubarik, Najoua El; Belabbes, Meryem Benchekroun; Boutimzine, Nouredine; Cherkaoui, Lalla Ouafae title: Syndrome de Stevens-Johnson induit par le vaccin COVID-19 de Sinopharm date: 2022-01-06 journal: J Fr Ophtalmol DOI: 10.1016/j.jfo.2021.12.005 sha: 0e0652c6a6a58ed16fead7acc045b14b44efd3e7 doc_id: 963147 cord_uid: w7ekq1us nan Stevens-Johnson syndrome (SJS) is a medical emergency. It is a rare potentially lethal adverse drug reaction. It is defined by an acute hypersensitivity reaction that causes extensive necrosis of the mucous membrane and skin (1) . The acute phase leads to an inflammation of the ocular surface. The chronic phase is marked with fibrosing conjunctivitis, corneal scarring and dry eye (2) . While the number of studies showing the efficacy of the COVID-19 vaccine are increasing day by day, its side effects remain unknown. We report a case of Stevens-Johnson syndrome following the administration of the second dose of Sinopharm COVID-19 vaccine (Chinese-WIBP-Vero-Inactivated-Covid). We report a case of a 32 year old African man, with no pathological history, who presented six hours after the second dose of sinopharm vaccine, blistering rash on his hands, erythematous plaque with peeling dermis on his chest, back, skull, face and neck, without exposure to any other drug ( figure 1: a There are three main approaches to producing COVID-19 vaccine. Their differences lie in whether they use the whole virus; or the part that triggers the immune system; or the genetic material that provides the instructions for making specific proteins and not the whole virus (16) . We report a case that illustrates an exceedingly rare complication of the COVID-19 vaccine. Given the important benefit of the vaccine in the current pandemic, such rare reactions should not deter people from receiving the vaccine. No conflict of interests. Stevens-Johnson syndrome: The role of an ophthalmologist Improved detection of disease progression in ocular cicatricial pemphigoid Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases Immunological response in Stevens-Johnson syndrome and toxic epidermal necrolysis Modes of presentation of chemical neoantigens to the immune system Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis Cutaneous T-cell recruitment in toxic epidermal necrolysis. Further evidence of CD8+ lymphocyte involvement Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis Proceedings of the 2021 National Toxicology Program Satellite Symposium Management of Stevens-Johnson Syndrome-Toxic Epidermal Necrolysis: Looking Beyond Guidelines! Stevens-Johnson syndrome: a case report Is there an association between Syndrome and vaccination? A systematic review Immune-mediated adverse reactions to vaccines The different types of COVID-19 vaccines VAXZEVRIA -COVID-19 Vaccine AstraZeneca SPIKEVAX -COVID-19 Vaccine Moderna Clinical and pathologic correlation of cutaneous COVID-19 vaccine reactions including V-REPP: A registry-based study Bullous drug eruption after second dose of mRNA-1273 (Moderna) COVID-19 vaccine: Case report Moderna COVID-19 vaccine induced skin rash Toxic Epidermal Necrolysis Post COVID-19 Vaccination -First Reported Case Stevens-Johnson syndrome post second dose of Pfizer COVID-19 vaccine: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol COVID-19 vaccine-induced Stevens-Johnson syndrome